PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA
Angle PLC (AIM:AGL) Molecular characterisation of CTCs
4d Pharma PLC (AIM:DDDD) ASCO 2022 MRx0518 and Bavencio Trial In Progress
4D pharma Presents Trial in Progress Poster on the Phase II Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the
Open Orphan PLC (AIM:ORPH) Completion of Nominated Adviser due diligence
Open Orphan plc (AIM: ORPH), is a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials.
Poolbeg Pharma PLC (AIM:POLB) US patents granted for POLB 001 and POLB 002
Further expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Angle PLC (AIM:AGL) receives FDA clearance for Parsortix
ANGLE ACHIEVES WORLD FIRST WITH FDA CLEARANCE FOR ITS PARSORTIX SYSTEM
Genflow Biosciences (LON:GENF) International patent application
Patent portfolio strengthened with international patent application under the Patent Cooperation Treaty
Immupharma PLC (AIM:IMM) Finals results for y/e 31 December 2021
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2021 (the
Open Orphan PLC (AIM:ORPH) Notice of results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces
Futura Medical PLC (AIM:FUM) MED3000 Collaboration in EEA, UK & Switzerland
Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland
Open Orphan PLC (AIM:ORPH) £7.3m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces
Abingdon Health PLC (AIM:ABDX) Significant contract to manufacture LFD components
Significant contract signed to manufacture lateral flow device components
